Who mentions $BMY most on Surfaced?

@jacobplieth (Jacob Plieth) mentions $BMY most — 50 mentions in the past 12 months.

When was $BMY first mentioned on Surfaced?

The earliest tracked mention of $BMY in the Surfaced archive was on Aug 29, 2025.

How many voices track $BMY?

7 FinTwit voices have mentioned $BMY 56 times in the past 12 months.

What kind of voices mention $BMY most?

$BMY is mentioned most by Biotech voices on Surfaced.

$BMY — FinTwit mentions on Surfaced

Recent mentions

72 mentions

@jacobpliethJul 17, 2026 · 7:20 AM

$TPST take on the various in vivo Car-T approaches $ABBV $LLY $AZN $RNAC $BMY https://t.co/GeaX9kk0B3

Open on X

@jacobpliethJun 26, 2026 · 1:02 PM

That one is especially curious since $MRNA hasn't disclosed the antigens targeted by mRNA-4106 or mRNA-4200. Does mRNA-4200 have anything to do with Lag3? $MRK $BMY

Open on X

@adamfeuersteinJun 12, 2026 · 7:09 PM

‘Synthetic lethality’ could trigger another round of biotech M&A $RVMD $TNGX $BMY $ERAS https://t.co/UQ7BPhLh6x

Open on X

@pelositrackerJun 12, 2026 · 2:13 PM

Something to keep an eye on Rep. Mike Kelly (R) just filed a sale of up to $50,000 of $BMY Kelly sits on the House Ways & Means Subcommittee on Health That subcommittee makes the Medicare laws that control how much the government pays for prescription drugs Including Bristol-Myers' biggest drug, Eliquis, is one where the government now sets the price

Open on X

@adamfeuersteinJun 8, 2026 · 10:46 PM

Re: PRMT5. I had forgotten until just now, but when $BMY bought Mirati, the deal included a CVR worth $1B ($12/share) for Mirati’s PRMT5 inhibitor, now known as navlimetostat. It pays out if Bristol files for approval by 2030. Of course, we know Bristol’s CVR track record …. @Biohazard3737 … so maybe this is even more bullish for $TNGX?

Open on X

@jacobpliethJun 1, 2026 · 1:31 PM

$RVMD $SMMT $BNTX $AZN $MRK $BMY $LLY $IDYA $JNJ $GILD $INCY $PFE $NVS $AVBP #Asco26

Open on X

@jacobpliethMay 31, 2026 · 10:12 PM

V nice story from @Angus_Fierce on trial design differences & changes for PD(L)1xVEGF bispecifics https://t.co/qDp3VbH0H2 $BNTX $PFE $BMY

Open on X

@jacobpliethMay 31, 2026 · 12:26 PM

Akeso's Harmoni-6 wins on survival. Now on to $SMMT Harmoni-3. Via @ApexOnco from #ASCO26 -> https://t.co/9Nj3NTaAI9 $BNTX $PFE $BMY $MRK

Open on X

@adamfeuersteinMay 29, 2026 · 9:35 PM

#ASCO26 Day 1. We're ASCOmaxxing. Positive data for Bristol $BMY in multiple myeloma and Pfizer $PFE in lung cancer. The FDA will surely convene an adcomm for $REPL, right? And Dizal's good day/bad day. https://t.co/NiENYMHswv via @statnews

Open on X

@ftr_investorsMay 20, 2026 · 12:11 PM

$BMY Bristol Myers Squibb announced a partnership with Anthropic to deploy its Claude AI model to more than 30,000 employees in an effort to accelerate the discovery, development, manufacturing, and delivery of new medicines 💊🤖 https://t.co/Kzi0oPFzAs

Open on X

@stocksavvyshayMay 14, 2026 · 12:41 PM

$TEM & $BMY are expanding their AI-driven clinical trial collaboration across 5 initial programs in oncology & neuroscience. The partnership uses Tempus Lens, multimodal real-world data & AI analytics to identify better patient segments & improve clinical trial success rates. https://t.co/XOlg8cACr4

Open on X

@adamfeuersteinMay 12, 2026 · 11:23 AM

Bristol Myers Squibb $BMY partners with China’s Hengrui Pharma on a dozen drugs https://t.co/KKpa1SsuCz via @DrewQJoseph

Open on X

@jacobpliethApr 30, 2026 · 11:34 AM

Krystal-10 was the (delayed) confirmatory trial, so does the FDA now rescind Krazati's accelerated approval in colorectal cancer? $BMY $AMGN

Open on X

@jacobpliethApr 30, 2026 · 11:22 AM

$BMY discontinues: BMS-986484 (CD40 x FAP MAb) RYZ101 in SCLC (still in ph3 for NETs, I think) Krazati in colorectal (ph3 Krystal-10 study gone!) https://t.co/ZTgvndoN5W

Open on X

@jacobpliethMar 25, 2026 · 4:13 PM

$MRK, a company with no CML presence, buys $TERN, a company that only pivoted to CML 2 years ago. And other surprises, via @apexonco -> https://t.co/MtOjGJmTfd $ELVN $NVS $PFE $BMY

Open on X

@adamfeuersteinMar 25, 2026 · 10:03 AM

@JacobPlieth FTC would have blocked a $NVS bid for $TERN, I think. $BMY buying $TERN made a lot of sense, and it needs it more than Merck. Maybe a higher bid is coming.

Open on X

@adamfeuersteinMar 25, 2026 · 9:37 AM

How did $BMY let $MRK buy $TERN?

Open on X

@jacobpliethMar 23, 2026 · 3:23 PM

$GILD picks KITE-753, and pits it head to head vs Yescarta (!). Via @ApexOnco -> https://t.co/lYZgRi0rge $BMY

Open on X

@jacobpliethMar 16, 2026 · 2:38 PM

Obv we're still desperate for more data on CCR8, but this $BMY imzokitug ph1/2 trial expansion is barely credible. 185 -> 949 patients?! https://t.co/gkyxNf2iX2

Open on X

@jacobpliethMar 16, 2026 · 2:37 PM

Since my 2024 look at CCR8 a lot has happened: $BMY $GILD $ABBV upsized; $ONC Bayer $ZLAB (& soon $AMGN?) discontinued. @BatirtzeAreitio investigates, via @ApexOnco -> https://t.co/hUweyScpAN $CHRS $RHHBY

Open on X

@jacobpliethMar 16, 2026 · 11:13 AM

Who knew $REGN was developing an anti-GPRC5D T-cell engager? https://t.co/jyL1PAS0y5 $JNJ $PFE $BMY

Open on X

@jacobpliethFeb 26, 2026 · 12:33 PM

$RVMD was collaborating with $TNGX in PRMT5, but now it's working with $BMY (remember that ex MRTX project?). Via @ByMadeleineA @ApexOnco -> https://t.co/mGZjKOiB7p (And $AMGN still dose optimising.)

Open on X

@jacobpliethFeb 9, 2026 · 1:52 PM

Important similarity between $LLY Orna's and $BMY Orbital's approaches to in vivo Car-T https://t.co/33fp8R6qnX

Open on X

@jacobpliethFeb 9, 2026 · 12:27 PM

So $LLY not interested in oncology applications of Orna's in vivo Car-T? $ABBV $AZN $BMY $GILD https://t.co/wB3rR5LID8

Open on X

@yasutaketinFeb 6, 2026 · 9:45 PM

$BMY ブリストル・マイヤーズスクイブ決算で2026年の業績見通しが市場予想を上回り、上昇。配当利回り4.18% https://t.co/Lb48ZJHnmp

Open on X

@adamfeuersteinFeb 2, 2026 · 2:06 PM

$BMY Patent expirations and recent pipeline setbacks has made the outcome of the Cobenfy Ph3 study in Alzheimer's agitation a crucial moment for Bristol Myers Squibb. @damiangarde reports... https://t.co/IKu1JRxZzy

Open on X

@adamfeuersteinJan 12, 2026 · 6:03 PM

$CYTK Blum announces Myqorzo WAC price of $108,400 -- "parity slight plus" relative to $BMY Camzyos #JPM26

Open on X

@jacobpliethJan 12, 2026 · 4:16 PM

$ABBV pays $650m for a seat at the PD-1 x VEGF bispecific table - and check out that waterfall. Biggest #JPM26 deal so far? Via @ApexOnco -> https://t.co/DV3smu5YSb $SMMT $MRK $BMY $BNTX

Open on X

@jacobpliethJan 12, 2026 · 3:04 PM

If you missed the #ESMOIO25 poster, high-dose RC148 + docetaxel showed cORR 67% (n=21) in post-checkpoint NSCLC; half of patients PD-L1-ve. Chinese data, but still! $ABBV $SMMT $BMY $BNTX

Open on X

@spaceinvestor_dJan 3, 2026 · 5:03 PM

IN-SPACE MANUFACTURING $RDW successfully cultivated protein seed crystals in space's microgravity environment, an achievement impossible on Earth. Now, they’re pursuing royalty agreements with major pharmaceutical players like $LLY and $BMY to leverage these crystals for drugs enhancement & development, aiming to revolutionize how medicines are made. 🗓️On June 3rd, they've been awarded a contract from Aspera Biomedicines, a pharmaceutical company specializing in the development of cancer stem cell targeted therapies, to conduct space-based research and analysis on a new cancer treatment. 🗓️In August, they launched SpaceMD, to commercialize pharmaceutical development in Space and signed a royalty agreement with ExesaLibero Pharma. In the same month, they also received $25M from NASA to provide biotechnology and support On-Orbit operations aboard the International Space Station. In-space manufacturing is projected to become a $60B+ market by 2040, with very few real competitors at the moment.

Open on X

@adamfeuersteinDec 19, 2025 · 9:06 PM

Here are the Myqorzo and Camzyos black box warnings side by side $CYTK $BMY https://t.co/XnO8QG0QnU

Open on X

@jacobpliethDec 15, 2025 · 11:05 AM

JS212, Junshi's me-too iza-bren, just had its US IND accepted $BMY https://t.co/SeQLDcyinN

Open on X

@jacobpliethDec 12, 2025 · 3:49 PM

$BMY sends $PFE $TAK Adcetris a shot across the bows. Via @ApexOnco -> https://t.co/JW2jzGpKHf

Open on X

@jacobpliethDec 12, 2025 · 2:06 PM

@B_C_1776 Maybe that's why $BMY waited 3 years before filing https://t.co/vJXPqDdAGh

Open on X

@jacobpliethDec 12, 2025 · 1:02 PM

Hands up who before yesterday had heard of the SWOG S1826 study... 8 Apr 2026 Pdufa date for $BMY Opdivo + chemo in 1L Hodgkin's where it beat $PFE $TAK Adcetris: 3yr PFS FU via Alex Herrera @ #ASH25 https://t.co/gKPGs5tTOx

Open on X

@jacobpliethDec 9, 2025 · 1:05 PM

$JNJ Tecvayli (& $LEGN Carvykti) "entering a new era of resetting survival expectations in a cancer historically described as incurable". @ByMadeleineA @ApexOnco from #ASH25 on Majestec-3 https://t.co/yUP2j9tJjj $ACLX $BMY

Open on X

@adamfeuersteinDec 8, 2025 · 8:05 PM

$BMY should buy $TERN $BMY needs to buy $TERN If everyone else can make M&A predictions on this site, so can I.

Open on X

@jacobpliethDec 5, 2025 · 9:46 AM

Denominator shenanigans continuing with Car-T therapy, this time in marginal zone lymphoma, where $BMY Breyanzi just got approved. Is the ORR 96% or 82%? You decide https://t.co/vnaePtFVBy

Open on X

@adamfeuersteinDec 3, 2025 · 12:05 PM

Bristol Myers Squibb $BMY Announces Continuation of Cobenfy ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease "the company identified irregularities due to clinical trial execution at a small number of study sites..." https://t.co/ghgNoJGBYd

Open on X

@adamfeuersteinNov 23, 2025 · 7:23 PM

Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention $BMY competitor https://t.co/yhK9lInluQ

Open on X

@jacobpliethNov 14, 2025 · 2:28 PM

@NotthatkindofDr I wonder if it's derived from $MRTX or some internal $BMY thing.

Open on X

@adamfeuersteinNov 14, 2025 · 12:08 PM

Big uh-oh for $BMY $JNJ Factor X1a anticoagulant program. Ph3 study halted for futility. https://t.co/amVbO86N6o

Open on X

@jacobpliethNov 14, 2025 · 11:00 AM

First-in-human study of BMS-986523 suggests that it might be a KRAS inhibitor of some sort $BMY https://t.co/Dx9K5cVcZB

Open on X

@jacobpliethNov 6, 2025 · 11:12 AM

$PFE moves its $1.25bn PD-1 x VEGF bispecific bet quickly into pivotal trials, with NSCLC & colorectal efforts mirroring $SMMT & $BNTX / $BMY. Via @ApexOnco -> https://t.co/cHrVj7CTpw

Open on X

@jacobpliethNov 3, 2025 · 12:03 PM

Here we go: 82% ORR with $CRBU CBP-010 (now has the INN vispacabtagene regedleucel). That compares with 83% for $GILD Yescarta, and 87% for $BMY Breyanzi, on a cross-trial basis.

Open on X

@adamfeuersteinOct 27, 2025 · 11:23 AM

CAR-T therapies from Cabaletta $CABA, Bristol Myers Squibb $BMY induce remissions in patients with autoimmune disorders https://t.co/Q3gqkkE8G5

Open on X

@jacobpliethOct 10, 2025 · 11:19 AM

Now $BMY buys Orbital for... $1.5bn! Focus seems to be autoimmune, but pipeline also includes some oncology work $AZN $ABBV $GILD $SNY $ALPMF https://t.co/rHXCOm2idI

Open on X

@jacobpliethSep 24, 2025 · 8:52 PM

Apparently #SITC25 is hosting a webinar on development of anti-CCR8 MAbs - mechanisms & clinical results. 22 Oct 2025 $CHRS $BMY $ABBV $RHHBY $AMGN $GILD $BGNE $FGEN $BNTX

Open on X

@jacobpliethSep 19, 2025 · 2:27 PM

Dragonfly's $ABBV deal over ABBV-303 appears to be the only one definitely still in place. $BMY terminated CC-96191 in Oct 2024. $MRK no longer mentions MK-4464. $GILD no progress on DF7001 since 2022.

Open on X

@jacobpliethSep 19, 2025 · 2:17 PM

$BMY confirms that it scrapped its 2017 NK-cell engager tie-up with Dragonfly. With $SNY $IPHA $AFMD $GTBP setbacks this modality looks like it's on borrowed time. Via @ApexOnco -> https://t.co/OCBrFB8P1P $MRK $ABBV $GILD

Open on X

@jacobpliethSep 17, 2025 · 3:46 PM

@tstamm7002 @ByMadeleineA Still has deals with $ABBV $MRK & $GILD. $BMY deal looks toast.

Open on X

@jacobpliethSep 8, 2025 · 1:07 PM

If you're catching up with #WCLC25 news, @ApexOnco coverage can be found here: https://t.co/Jl2xGAtcZw $SMMY $IDYA $AZN $JNJ $BMY $ZLAB $BNTX

Open on X

@jacobpliethSep 7, 2025 · 7:23 PM

More doubts for $SMMT as the Harmoni guessing game continues at #WCLC25. Via @ApexOnco -> https://t.co/riemtQP53v $BNTX $TIL $BMY

Open on X

@jacobpliethSep 4, 2025 · 7:10 AM

$BNTX starting phase 1 with its version of iza-bren $BMY (BNT3212 = EGFR x Her3 ADC)

Open on X

@adamfeuersteinAug 30, 2025 · 10:46 AM

Cytokinetics $CYTK drug yielded benefits over common therapy in patients with heart condition, study shows https://t.co/pg3egDxRwq $BMY

Open on X

@jacobpliethAug 29, 2025 · 4:11 PM

#WCLC25 press briefing schedule is out Sat 6 Sep: two iza-bren studies $BMY Sun 7 Sep: Harmoni $SMMT & Arros-1 $NUVL Tue 9 Sep: $CADL

Open on X

@jacobpliethAug 20, 2025 · 4:19 PM

#WCLC25 late-breaker & plenary preview, via @ApexOnco https://t.co/VJj3Bocr0A $SMMT $BMY $BNTX $NUVL $CGEM

Open on X

@adamfeuersteinAug 19, 2025 · 2:09 PM

"Pharm to table" It's the clever buzzphrase bandied around by pharma insiders when promoting their plans to sell drugs directly to consumers. Cut out the insurers and the PBMs and we can lower drug prices (and get Trump off our collective backs), or so the pharma strategy goes. Except as my colleague @elaineywchen reports today, direct-to-consumer programs championed by $LLY $NVO $BMY $PFE and others are unlikely to make drugs more affordable. Drug makers may benefit in other ways, but consumers less so. Story link below....

Open on X

@jacobpliethAug 13, 2025 · 12:00 PM

What's up with the HK IPO of Biokin (Systimmune)? The resubmitted IPO document seems to have lapsed https://t.co/zHx7drGxiW $BMY

Open on X

@jacobpliethAug 1, 2025 · 2:53 PM

@Ivaj960612 @jq1234t $BMY https://t.co/s90FNBAO94

Open on X

@jacobpliethJul 31, 2025 · 2:02 PM

Did $TIL get a bargain when it bought a PD-L1 x VEGF bispecific from Immuneonco? You decide. Via @ApexOnco -> https://t.co/kwsOLp3y4f $SMMT $BNTX $BMY $PFE $MRK

Open on X

@spaceinvestor_dJul 19, 2025 · 1:18 PM

SPACE GROWN CRYSTALS & MORE $RDW successfully cultivated protein seed crystals in space's microgravity environment, an achievement impossible on Earth. Now, they’re pursuing royalty agreements with major pharmaceutical players like $LLY and $BMY to leverage these crystals for drugs enhancement & development, aiming to revolutionize how medicines are made. On June 3rd, they've been awarded a contract from Aspera Biomedicines, a pharmaceutical company specializing in the development of cancer stem cell targeted therapies, to conduct space-based research and analysis on a new cancer treatment. In January 2025, $SPCE announced a strategic collaboration with Redwire to build plug-and-play research payload lockers for its upcoming Delta-class spaceplanes. Opening a pipeline of opportunies with other commercial space companies. @redwire is quickly becoming a leader in In-space manufacturing, a sector projected to become a $63 billion market by 2040 and with minimal competition. This isn’t just about space. It’s about redefining the future of medicine.

Open on X

@jacobpliethJul 17, 2025 · 1:22 PM

...and more, this time from the FDA's Andrea Baines $BMY $JNJ $GSK $LEGN https://t.co/8UEG4QyKPq

Open on X

@jacobpliethJul 17, 2025 · 12:18 PM

Admirable effort by FDA's Deepti Telajara to present the current treatment paradigm for multiple myeloma $JNJ $BMY $GSK https://t.co/VfdzITcqRY

Open on X

@jacobpliethJul 11, 2025 · 9:57 PM

Huh?! $JNJ $LEGN $BMY

Open on X

@jacobpliethJul 4, 2025 · 10:11 AM

Guess who's about to take a SC anti-PD-1 into phase 3? Via @ApexOnco -> https://t.co/TNXStCSSIo $ONC $BGNE $RHHBY $AZN $MRK $BMY $PFE

Open on X

@jacobpliethJun 16, 2025 · 8:15 AM

PD-1 x VEGF is all very well, but how about PD-1 x Lag-3? 3SBio reckons it's worth taking into the clinic https://t.co/hPaa5ThMgd $PFE $BMY

Open on X

@jacobpliethJun 9, 2025 · 3:49 PM

Is $BMY BMS-986500 a CDK2 inhibitor? https://t.co/0GKMRRiKLm $PFE $RHHBY https://t.co/0NCG2palqG

Open on X

@jacobpliethJun 6, 2025 · 8:53 AM

Quite the tangled web: Dualitybio's Her2 ADC trastuzumab pamirtecan is licensed to $BNTX (of $BMY PD-L1 x VEGF fame) ex-China, and to 3SBio (of $PFE PD-1 x VEGF fame) in China.

Open on X

@jacobpliethJun 2, 2025 · 5:48 PM

How $BNTX turned $800m into $1.5bn, via @ApexOnco -> https://t.co/5BVk9OWMYr Who will be next? #ASCO25 $BMY $PFE $SMMT $TIL

Open on X

@jacobpliethJun 2, 2025 · 12:05 PM

Also: $TIL got passed over by big pharma for the second time in two weeks?? $BNTX $BMY $SMMT $PFE

Open on X

@jacobpliethJun 2, 2025 · 11:49 AM

So $BNTX turns $800m into $1.5bn in the space of 7mths, while $BMY makes $PFE look like it picked up a bargain. Long live PD-(L)1 x VEGF!

Open on X

$BMY

$BMY

About this stock

Frequently asked

Related stocks